Product Introduction:
Akt-3 Kit is a fixed-dose combination therapy used in the initial phase of tuberculosis (TB) treatment. It combines three potent antitubercular agents—Rifampicin (450 mg), Isoniazid (300 mg), and Ethambutol (800 mg)—to effectively combat Mycobacterium tuberculosis, the bacterium responsible for TB. This combination ensures a comprehensive approach to TB treatment by targeting the bacteria through multiple mechanisms. ​
Uses:
- Treatment of active pulmonary and extrapulmonary tuberculosis.​
Benefits:
- Combines three essential antitubercular drugs in a single kit, simplifying the treatment regimen.
- Enhances patient compliance due to reduced pill burden.
- Minimizes the risk of drug resistance by attacking the bacteria through different mechanisms.​
Composition:
- Rifampicin – 450 mg
- Isoniazid – 300 mg
- Ethambutol – 800 mg​
Side Effects:
Common side effects may include:
- Nausea, vomiting, and diarrhea.
- Loss of appetite and abdominal discomfort.
- Discoloration of urine, sweat, saliva, and tears (reddish-orange hue).
- Visual disturbances, such as blurred vision or color vision impairment.
- Tingling or numbness in hands and feet.
- Liver function abnormalities. ​
Safety Advice:
- Alcohol: Avoid alcohol consumption during treatment, as it may increase the risk of liver damage.
- Pregnancy and Breastfeeding: Use only if prescribed by a healthcare professional after assessing the benefits and risks.
- Liver and Kidney Function: Regular monitoring is advised, especially in patients with pre-existing liver or kidney conditions.
- Vision: Periodic eye examinations are recommended due to the risk of visual side effects associated with Ethambutol.
- Adherence: Complete the full course of therapy as prescribed, even if symptoms improve, to prevent the development of drug-resistant TB strains.
